The Efficacy and Safety of Rifaximin Treatment
Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV
About this trial
This is an interventional treatment trial for Liver Failure, Acute on Chronic
Eligibility Criteria
Inclusion Criteria: The confirmed HBsAg positive patients with chronic hepatitis B are defined as HBsAg positive for at least 6 months or evidence of chronic HBV infection; Acute onset, progressive deepening of jaundice, serum total bilirubin (TB) ≥ 85umol/L and severe coagulation dysfunction, international standardized ratio (INR) ≥ 1.5 or plasma prothrombin activity (PTA)<40% The score of the psychological test scale of hepatic encephalopathy is less than - 4 points or mild to moderate (degree I or II) manifestations of hepatic encephalopathy, including the decline of computational ability, timing and orientation, personality change, lethargy, and positive flapping wing tremor. Be able and willing to provide informed consent and comply with the test requirements. Exclusion Criteria: There are definite infections or hepatorenal syndromes during screening; Upper gastrointestinal bleeding occurred within 1 week before screening; Have used sedative drugs such as "benzodiazepines" or other psychotropic drugs within one week before screening; Those with severe primary heart, lung, kidney and other important organ dysfunction affecting life expectancy; HIV infection; Uncontrolled malignant tumor, nerve and mental abnormality; Patients who are allergic to the study drugs and excipients; Pregnant or lactating women; In the late stage of liver failure, MELD score>35; Other circumstances in which the researcher believes that the patient should not participate in this study.
Sites / Locations
- The Third Affiliated Hospital of Sun Yat-sen UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Rifaximin Treatment Group
Standard Treatment Group (control group)